CT影像组学特征预测晚期肺腺癌表皮生长因子受体突变状态及表皮生长因子受体酪氨酸激酶抑制剂治疗敏感性的效能

目的 应用CT影像组学特征预测晚期肺腺癌表皮生长因子受体(EGFR)的突变状态,筛选EGFR酪氨酸激酶抑制剂(EGFR?TKIs)治疗的优势人群.方法 回顾性分析行EGFR突变检测的253例晚期肺腺癌患者的临床资料.选取患者治疗前平扫期、动脉期和静脉期CT图像,每组CT提取715个影像组学特征.应用Lasso?logistic回归模型和10折交叉验证方法,分析预测EGFR突变的状态,筛选EGFR?TKIs治疗敏感人群的影像组学特征.结果 EGFR突变状态验证组单时相(平扫期、动脉期和静脉期)的受试者工作特征曲线下面积( AUC)分别为0.763、0.807和0.808,三时相所提取的影像组学特...

Full description

Saved in:
Bibliographic Details
Published in中华肿瘤杂志 Vol. 41; no. 4; pp. 282 - 287
Main Authors 杨春生, 陈卫东, 巩贯忠, 李振江, 仇清涛, 尹勇
Format Journal Article
LanguageChinese
Published 济宁市第一人民医院肿瘤科272000%山东省肿瘤医院放射物理技术科,济南,250117 01.04.2019
Subjects
Online AccessGet full text
ISSN0253-3766
DOI10.3760/cma.j.issn.0253-3766.2019.04.007

Cover

Loading…
Abstract 目的 应用CT影像组学特征预测晚期肺腺癌表皮生长因子受体(EGFR)的突变状态,筛选EGFR酪氨酸激酶抑制剂(EGFR?TKIs)治疗的优势人群.方法 回顾性分析行EGFR突变检测的253例晚期肺腺癌患者的临床资料.选取患者治疗前平扫期、动脉期和静脉期CT图像,每组CT提取715个影像组学特征.应用Lasso?logistic回归模型和10折交叉验证方法,分析预测EGFR突变的状态,筛选EGFR?TKIs治疗敏感人群的影像组学特征.结果 EGFR突变状态验证组单时相(平扫期、动脉期和静脉期)的受试者工作特征曲线下面积( AUC)分别为0.763、0.807和0.808,三时相所提取的影像组学特征分别为5、18、23个,可区分EGFR突变状态. EGFR?TKIs敏感验证组单时相(平扫期、动脉期和静脉期)的AUC值分别为0.730、0.833、0.895,三时相所提取的影像组学特征分别为3、7、22个,可筛选EGFR?TKIs治疗敏感的优势人群.静脉期CT图像特征在预测EGFR突变状态、EGFR?TKIs治疗敏感性方面的效能显著高于平扫期和动脉期.结论 不同时相的CT扫描影像组学特征均可作为预测肺腺癌EGFR突变状态、筛选EGFR?TKIs治疗优势人群的无创手段,有利于提高中晚期肺腺癌患者靶向治疗的效能.
AbstractList 目的 应用CT影像组学特征预测晚期肺腺癌表皮生长因子受体(EGFR)的突变状态,筛选EGFR酪氨酸激酶抑制剂(EGFR?TKIs)治疗的优势人群.方法 回顾性分析行EGFR突变检测的253例晚期肺腺癌患者的临床资料.选取患者治疗前平扫期、动脉期和静脉期CT图像,每组CT提取715个影像组学特征.应用Lasso?logistic回归模型和10折交叉验证方法,分析预测EGFR突变的状态,筛选EGFR?TKIs治疗敏感人群的影像组学特征.结果 EGFR突变状态验证组单时相(平扫期、动脉期和静脉期)的受试者工作特征曲线下面积( AUC)分别为0.763、0.807和0.808,三时相所提取的影像组学特征分别为5、18、23个,可区分EGFR突变状态. EGFR?TKIs敏感验证组单时相(平扫期、动脉期和静脉期)的AUC值分别为0.730、0.833、0.895,三时相所提取的影像组学特征分别为3、7、22个,可筛选EGFR?TKIs治疗敏感的优势人群.静脉期CT图像特征在预测EGFR突变状态、EGFR?TKIs治疗敏感性方面的效能显著高于平扫期和动脉期.结论 不同时相的CT扫描影像组学特征均可作为预测肺腺癌EGFR突变状态、筛选EGFR?TKIs治疗优势人群的无创手段,有利于提高中晚期肺腺癌患者靶向治疗的效能.
Abstract_FL Objective To explore the ability of computed?tomography ( CT) radiomic features to predict the Epidermal growth factor receptor ( EGFR ) mutation status and the therapeutic response of advanced lung adenocarcinoma to EGFR? Tyrosine kinase inhibitors ( TKIs ) treatment. Methods A retrospective analysis was performed on 253 patients diagnosed as advanced lung adenocarcinoma, who underwent EGFR mutation detection, and those with EGFR sensitive mutation were treated with TKIs. Using the Lasso regression model and the 10 fold cross?validation method, the radiomic features of predicted EGFR mutation status and the screening of TKIs for sensitive populations were obtained.715 radiomic features were extracted from unenhanced, arterial phase and venous phase, respectively. Results The area under curve (AUC) values of the multi?phases including unenhanced, arterial phase and venous phase of the EGFR mutation status validation group were 0.763, 0.807 and 0.808, respectively. The number of radiomic features extracted from the multi?phases were 5, 18 and 23, respectively, which could distinguish the EGFR mutation status. The AUC values of the multi?phases of the EGFR?TKIs sensitive validation group were 0.730, 0.833 and 0.895, respectively. The number of radiomic features extracted from the multi?phases were 3, 7 and 22, respectively, which can be used to screen the superior population for TKIs treatment. The efficiency of radiomic features extracted from venous phase in predicting EGFR mutant status and EGFR?TKIs sensitivity was significantly superior than those of unenhanced and arterial phase. Conclusions The radiomic features of CT scanning can be used as the radiomics biomarker to predict the EGFR mutation status of lung adenocarcinoma and to further screen the dominant population in TKIs therapy, which provides the basis for targeted therapy.
Author 巩贯忠
仇清涛
杨春生
尹勇
李振江
陈卫东
AuthorAffiliation 济宁市第一人民医院肿瘤科272000%山东省肿瘤医院放射物理技术科,济南,250117
AuthorAffiliation_xml – name: 济宁市第一人民医院肿瘤科272000%山东省肿瘤医院放射物理技术科,济南,250117
Author_FL Yin Yong
Chen Weidong
Yang Chunsheng
Li Zhenjiang
Qiu Qingtao
Gong Guanzhong
Author_FL_xml – sequence: 1
  fullname: Yang Chunsheng
– sequence: 2
  fullname: Chen Weidong
– sequence: 3
  fullname: Gong Guanzhong
– sequence: 4
  fullname: Li Zhenjiang
– sequence: 5
  fullname: Qiu Qingtao
– sequence: 6
  fullname: Yin Yong
Author_xml – sequence: 1
  fullname: 杨春生
– sequence: 2
  fullname: 陈卫东
– sequence: 3
  fullname: 巩贯忠
– sequence: 4
  fullname: 李振江
– sequence: 5
  fullname: 仇清涛
– sequence: 6
  fullname: 尹勇
BookMark eNp1kEtLAlEcxe_CIDM_RtDG6X_njo4uQ3qB0Ma93HmVYiM0RODKJ5gFFmU-CqwWJYJRQVKK-WW69zrfIqNo1-ocfhzOgbOAPHbGNhFaxiARNQQr-h6VUlLScWwJ5CAJzGBIkgFHJFAkANWDvH98HvkdJ6lBMBxUlQhWvagZjbPxMyvWxKjE-vfi6J195N27En895q02v-5MC8NpeShaJ9Pbrmg_iouOW5-wqxvWP2W1xuf4XPTyrNYU1QHPzUz1v5hb7vGnrlt-45OcWx7w6hmrDNhRgb-MxGWD12u81OG5B9Eu8XplWhwvojmLph3T_6s-FF9fi0c3A7Htja3oaizgYAASUCwCWAVqQMSiOlVM07C0kIx1QmUIa2CGVVnD1KSmqamGJRtqmGi6QvQQNmRFJj609FN7SG2L2juJVOZg354NJrK72fT3jaAAJuQLZ4ak3Q
ContentType Journal Article
Copyright Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
Copyright_xml – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
DBID 2B.
4A8
92I
93N
PSX
TCJ
DOI 10.3760/cma.j.issn.0253-3766.2019.04.007
DatabaseName Wanfang Data Journals - Hong Kong
WANFANG Data Centre
Wanfang Data Journals
万方数据期刊 - 香港版
China Online Journals (COJ)
China Online Journals (COJ)
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
DocumentTitle_FL Application of radiomics captured from CT to predict the EGFR mutation status and TKIs therapeutic sensitivity of advanced lung adenocarcinoma
EndPage 287
ExternalDocumentID zhzl201904013
GrantInformation_xml – fundername: 山东省重点研发计划(2018GSF118006) Fund program: Key Research and Development Program of Shandong Province
  funderid: (2018GSF118006)
GroupedDBID ---
-05
123
2B.
4A8
92F
92I
93N
ABDBF
ABJNI
ACGFS
ACUHS
ALMA_UNASSIGNED_HOLDINGS
CCEZO
CIEJG
CW9
EOJEC
OBODZ
PSX
TCJ
TGQ
U1G
U5O
ID FETCH-LOGICAL-s1003-4f30170ad09faca4eedfb621c3a208b0e872b1aeaeeb7df2d783bc43c61d2423
ISSN 0253-3766
IngestDate Thu May 29 04:00:01 EDT 2025
IsPeerReviewed false
IsScholarly true
Issue 4
Keywords [Subject words] Lung neoplasms
[主题词] 肺肿瘤
影像组学
表皮生长因子受体酪氨酸激酶抑制剂
Epidermal growth factor receptor?tyrosine kinase inhibitors
表皮生长因子受体
Epidermal growth factor receptor
Radiomics
Language Chinese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-s1003-4f30170ad09faca4eedfb621c3a208b0e872b1aeaeeb7df2d783bc43c61d2423
PageCount 6
ParticipantIDs wanfang_journals_zhzl201904013
PublicationCentury 2000
PublicationDate 2019-04-01
PublicationDateYYYYMMDD 2019-04-01
PublicationDate_xml – month: 04
  year: 2019
  text: 2019-04-01
  day: 01
PublicationDecade 2010
PublicationTitle 中华肿瘤杂志
PublicationTitle_FL Chinese Journal of Oncology
PublicationYear 2019
Publisher 济宁市第一人民医院肿瘤科272000%山东省肿瘤医院放射物理技术科,济南,250117
Publisher_xml – name: 济宁市第一人民医院肿瘤科272000%山东省肿瘤医院放射物理技术科,济南,250117
SSID ssib058574917
ssib051368316
ssib007279245
ssib000995398
ssj0042033
ssib006576341
ssib001103529
Score 2.2285104
Snippet 目的 应用CT影像组学特征预测晚期肺腺癌表皮生长因子受体(EGFR)的突变状态,筛选EGFR酪氨酸激酶抑制剂(EGFR?TKIs)治疗的优势人群.方法...
SourceID wanfang
SourceType Aggregation Database
StartPage 282
Title CT影像组学特征预测晚期肺腺癌表皮生长因子受体突变状态及表皮生长因子受体酪氨酸激酶抑制剂治疗敏感性的效能
URI https://d.wanfangdata.com.cn/periodical/zhzl201904013
Volume 41
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NixRHFG_MLoRcJCGRfKh4sCCXWfujqrrqWNXTgwjJaQLepHumRwnJCnG97GnVXdA1sAm6UTeBTXJQEQxJIIsfbPxn7O6d_yLvva6ZaT-CUQJDU7x-Xe_3Prr6vZ6qas87WhQQFXI06EQizjtc5ryjeaA6AmIB9_iBc7hQ-LPP5fEv-ImT4uS--ag1a-n8Ur4wWH7pupI38SrQwK-4SvY1PDvtFAjQBv_CETwMx__k46TPUsFsl9kAGypiqsfSmFnLFEeK6TIjkaI0s5qYU8gdWaqZCYlHMgsXWmxozbShRsI09KOYCpk11BDUiJFHJUgxATOKKIaZlBqcroJOgLmHsrRlxncwNDUAno5ZyhGzjvAqYwhPc4o6VIZZiTCUPzulzP8nVKM6hjS1PnVIFKuI0kO5jtLAMEw3MBRRBBoTLIPMIZoaYUgSIREGukCibXXPaWFih7kxuKau0KoRQGpXBwRSIXKU0mUqnXiB3Ar2MU0PXQJAKutpIuHOGNIDecXUQjMWTS5UToCxTqROZizQLfhFo2jLmek5QcZ_ThCikxgOhhSFGHSC3EukQLfmHuFtP4m2lNyTOu9a0hBDIcFfgwd9wDHm7MRPzgcJWZy0gAh-iXViNLcO8I9__AC5IBEB3SFOU2JOSPqLl78oQqIJLWEGGIq72wkNFGOEqUmUIGa6eUxvCgNGsGe0BpvjntQJlARBs5rYPYVDEeFTWLZThmavNjc08vbzv_mSlkslwyaXfD5LwXloMLQMvs4WviQhC1MhONdULzQ7-s8ytOm82eUzy18hh49vRd7y5kOojcM5b97Yru21qiYt2rt6QoYPZdasapECkopWFRTjJqKzyQUiiKSKZlWjUCLm9FanSXB56Ec0cWcC-m3vU6fVsVfpREsjF0fZ4ulWFt9_19vvyu8jphlL3_P2LZ9537uZ9MvdP8pLG_Xj1fL-7frKw_LvC-NfV6u_rla3tqqftvcuPtpbe1Tf-nbvl7v11m_19e3x5pPyx5_L-9-VGzee7l6r710oN27W6zvVCjTW_41tvHav-v3ueO1B9WRlvLZTrX9fXt4pr1ys_nxc_3Cj2tyoVrerlTv11mq1eXnv0u4HXr-X9pPjHffFms65ACf58lGE-5FlQ1-PskHGoQAZ5TIMBlEW-ir3CxWHeZAVWVHk8XAUDmMV5QMeDWQwxML2gDe3eHax-NA7IjiUlkNZRCIf4p6uKvDVqBjlsVBFBkXaR95hZ8hT7oF07tQz0fHxqxg-8d6ZjQQHvbmlb84Xh6DAWsoPu4D6B6aIL2c
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CT%E5%BD%B1%E5%83%8F%E7%BB%84%E5%AD%A6%E7%89%B9%E5%BE%81%E9%A2%84%E6%B5%8B%E6%99%9A%E6%9C%9F%E8%82%BA%E8%85%BA%E7%99%8C%E8%A1%A8%E7%9A%AE%E7%94%9F%E9%95%BF%E5%9B%A0%E5%AD%90%E5%8F%97%E4%BD%93%E7%AA%81%E5%8F%98%E7%8A%B6%E6%80%81%E5%8F%8A%E8%A1%A8%E7%9A%AE%E7%94%9F%E9%95%BF%E5%9B%A0%E5%AD%90%E5%8F%97%E4%BD%93%E9%85%AA%E6%B0%A8%E9%85%B8%E6%BF%80%E9%85%B6%E6%8A%91%E5%88%B6%E5%89%82%E6%B2%BB%E7%96%97%E6%95%8F%E6%84%9F%E6%80%A7%E7%9A%84%E6%95%88%E8%83%BD&rft.jtitle=%E4%B8%AD%E5%8D%8E%E8%82%BF%E7%98%A4%E6%9D%82%E5%BF%97&rft.au=%E6%9D%A8%E6%98%A5%E7%94%9F&rft.au=%E9%99%88%E5%8D%AB%E4%B8%9C&rft.au=%E5%B7%A9%E8%B4%AF%E5%BF%A0&rft.au=%E6%9D%8E%E6%8C%AF%E6%B1%9F&rft.date=2019-04-01&rft.pub=%E6%B5%8E%E5%AE%81%E5%B8%82%E7%AC%AC%E4%B8%80%E4%BA%BA%E6%B0%91%E5%8C%BB%E9%99%A2%E8%82%BF%E7%98%A4%E7%A7%91272000%25%E5%B1%B1%E4%B8%9C%E7%9C%81%E8%82%BF%E7%98%A4%E5%8C%BB%E9%99%A2%E6%94%BE%E5%B0%84%E7%89%A9%E7%90%86%E6%8A%80%E6%9C%AF%E7%A7%91%2C%E6%B5%8E%E5%8D%97%2C250117&rft.issn=0253-3766&rft.volume=41&rft.issue=4&rft.spage=282&rft.epage=287&rft_id=info:doi/10.3760%2Fcma.j.issn.0253-3766.2019.04.007&rft.externalDocID=zhzl201904013
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzhzl%2Fzhzl.jpg